Cimeio Therapeutics https://validator.w3.org/feed/docs/rss2.html Cimeio Therapeutics Therapy Platform Featured in Forbes Article News Cimeio Therapeutics Announces Publication in Nature Demonstrating That CD45 ADC and Shielded HSCs Represent a Potentially Universal Therapy for Blood Cancers Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies Lukas Home Page Cimeio Therapeutics Presents SCIP Platform Proof-of-Concept Data at ASH Cimeio Therapeutics Presents Additional Proof-of-Concept Data for SCIP Platform Cimeio Therapeutics Presents Data for its CD45 Universal Heme ADC at ASH Cimeio Therapeutics Announces Poster Presentations at ASH 2023 Steffi Home Page About Us Molecular shielding of CD52 retains expression, anti-phagocytic ‘don’t eat me’ function and protects from Alemtuzumab-mediated depletion Careers Disclaimer Privacy Statement (ZA) Privacy Statement (AU) Cookie Policy (BR) Cookie Policy (ZA) Privacy Statement (BR) Cookie Policy (AU) Privacy Statement (CA) Cookie Policy (CA) Privacy Statement (UK) Cookie Policy (UK) Privacy Statement (EU) Opt-out preferences Privacy Statement (US) Cookie Policy (EU) Cimeio Therapeutics Presents Data for its CD52 Shielding Variant at ASGCT Contact Us Publications Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy Coming Soon Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform Cimeio Therapeutics Announces Research Collaboration With the University of Pennsylvania Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A Function-Preserving Single Amino Acid Substitutions Shield Hematopoietic Stem and Progenitor Cells from CD117-Targeted Immunotherapy in Vivo Engineered Single Amino Acid Substitutions Protect Hematopoietic Stem and Progenitor Cells From CD123 Targeted Immunotherapy Molecular Shielding of the Pan-Hematopoietic Marker CD45 May Enable a Targeted Universal Approach for Replacement of the Hematopoietic System Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic Diseases Base-Edited HSPCs Are Shielded from Targeted CD33 Therapy but Preserve CD33 Expression Home Cimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome Selective haematological cancer eradication with preserved haematopoiesis Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline